SecBot SecBot
SECBOTREPLAY Home › Report › KYMR

KYMR · Jeremy Chadwick, an officer of Kymera Therapeutics, filed a Form 144 to…

Kymera Therapeutics, Inc. · 144 filed Apr 1, 2026 at 16:42 ET

At the news

NEUTRALIMPACT 3/10

144 filed Apr 1, 2026 at 16:42 ET

Jeremy Chadwick, an officer of Kymera Therapeutics, filed a Form 144 to report the proposed sale of 14,640 shares, following a series of recent 10b5-1 plan sales totaling over $12.1M in the past month. This filing is part of an ongoing, pre-arranged selling plan and not an isolated event.

  • Jeremy Chadwick, an officer of Kymera Therapeutics, filed Form 144 to propose the sale of 14,640 common shares.
  • The sale is part of a 10b5-1 trading plan, with recent sales already executed: 7,600 shares (~$649K) on 03/31/2026, 24,727 shares (~$1.98M) on 03/25/2026, 91,250 shares (~$7.06M) on 03/23/2026, and others totaling over $12.1M in the past month.
  • The proposed sale proceeds will be received in cash and are not tied to any new insider decision, as 10b5-1 plans are pre-scheduled.
  • Recent insider activity shows 4 sell transactions in the last 30 days totaling $3.8M, consistent with this pattern.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access